Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?

被引：19

作者：

Skeith, Leslie ^{[1
]}

Le Gal, Gregoire ^{[2
]}

Rodger, Marc A. ^{[3
]}

机构：

[1] Univ Calgary, Dept Med, Div Hematol & Hematol Malignancies, Calgary, AB, Canada

[2] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON, Canada

[3] McGill Univ, Dept Med, Montreal, PQ, Canada

来源：

THROMBOSIS RESEARCH | 2021年 / 202卷

关键词：

Venous thromboembolism; Contraceptives; oral; Estrogen replacement therapy; FACTOR-V-LEIDEN; RECURRENCE RISK; WOMEN; THROMBOSIS; YOUNG; THROMBOPHILIA; METAANALYSIS; COAGULATION; KNEE; VTE;

D O I：

10.1016/j.thromres.2021.03.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Exogenous hormone therapies, such as combined oral contraceptives (COC) and hormone replacement therapy (HRT), cause blood hypercoagulability and are a risk factor for venous thromboembolism (VTE). There is controversy on how strong this "provoking" risk factor is, and how other risk factors may synergise VTE risk. We aim to review the latest literature on the risk of initial and recurrent VTE with COC and HRT use to provide guidance for decision-making about duration of anticoagulation, and guide future research efforts.

引用

页码：134 / 138

页数：5